BACKGROUND:Morbidity and mortality patterns among pregnant women and their infants (before antiretroviral therapy was widely available) determines HIV-1 diagnostic, monitoring, and care interventions. METHODS: Data from mothers and their infants enrolled in a trial of antibiotics to reduce mother-to-child-transmission of HIV-1 at 4 sub-Saharan African sites were analyzed. Women were enrolled during pregnancy and follow-up continued until the infants reached 12 months of age. We describe maternal and infant morbidity and mortality in a cohort of HIV-1-infected and HIV-1-uninfected mothers. Maternal and infant factors associated with mortality risk in the infants were assessed using Cox proportional hazard modeling. RESULTS: Among 2292 HIV-1-infected mothers, 166 (7.2%) had a serious adverse event (SAE) and 42 (1.8%) died, whereas no deaths occurred among the 331 HIV-1 uninfected mothers. Four hundred twenty-four (17.8%) of 2383 infants had an SAE and 349 (16.4%) died before the end of follow-up. Infants with early HIV-1 infection (birth to 4-6 weeks) had the highest mortality. Among infants born to HIV-1-infected women, maternal morbidity and mortality (P = 0.0001), baseline CD4 count (P = 0.0002), and baseline plasma HIV-1 RNA concentration (P < 0.0001) were significant predictors of infant mortality in multivariate analyses. CONCLUSIONS: The high mortality among infants with early HIV-1 infection supports access to HIV-1 diagnostics and appropriate early treatment for all infants of HIV-1-infected mothers. The significant association between stage of maternal HIV-1 infection and infant mortality supports routine CD4 counts at the time of prenatal HIV-1 testing.
RCT Entities:
BACKGROUND: Morbidity and mortality patterns among pregnant women and their infants (before antiretroviral therapy was widely available) determines HIV-1 diagnostic, monitoring, and care interventions. METHODS: Data from mothers and their infants enrolled in a trial of antibiotics to reduce mother-to-child-transmission of HIV-1 at 4 sub-Saharan African sites were analyzed. Women were enrolled during pregnancy and follow-up continued until the infants reached 12 months of age. We describe maternal and infant morbidity and mortality in a cohort of HIV-1-infected and HIV-1-uninfected mothers. Maternal and infant factors associated with mortality risk in the infants were assessed using Cox proportional hazard modeling. RESULTS: Among 2292 HIV-1-infected mothers, 166 (7.2%) had a serious adverse event (SAE) and 42 (1.8%) died, whereas no deaths occurred among the 331 HIV-1 uninfected mothers. Four hundred twenty-four (17.8%) of 2383 infants had an SAE and 349 (16.4%) died before the end of follow-up. Infants with early HIV-1 infection (birth to 4-6 weeks) had the highest mortality. Among infants born to HIV-1-infectedwomen, maternal morbidity and mortality (P = 0.0001), baseline CD4 count (P = 0.0002), and baseline plasma HIV-1 RNA concentration (P < 0.0001) were significant predictors of infant mortality in multivariate analyses. CONCLUSIONS: The high mortality among infants with early HIV-1 infection supports access to HIV-1 diagnostics and appropriate early treatment for all infants of HIV-1-infected mothers. The significant association between stage of maternal HIV-1 infection and infant mortality supports routine CD4 counts at the time of prenatal HIV-1 testing.
Authors: Julia E Aledort; Allan Ronald; Sylvie M Le Blancq; Renee Ridzon; Alan Landay; Maria E Rafael; Molly V Shea; Jeff Safrit; Rosanna W Peeling; Nicholas Hellmann; Peter Mwaba; King Holmes; Cathy Wilfert Journal: Nature Date: 2006-11-23 Impact factor: 49.962
Authors: Robert L Goldenberg; Victor Mudenda; Jennifer S Read; Elizabeth R Brown; Moses Sinkala; Steve Kamiza; Francis Martinson; Ephata Kaaya; Irving Hoffman; Wafaie Fawzi; Megan Valentine; Taha E Taha Journal: Am J Obstet Gynecol Date: 2006-07-26 Impact factor: 8.661
Authors: Taha E Taha; Elizabeth R Brown; Irving F Hoffman; Wafaie Fawzi; Jennifer S Read; Moses Sinkala; Francis E A Martinson; George Kafulafula; Gernard Msamanga; Lynda Emel; Samuel Adeniyi-Jones; Robert Goldenberg Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: Bradley C Fetzer; Mina C Hosseinipour; Portia Kamthuzi; Lisa Hyde; Brian Bramson; Kebba Jobarteh; Kristine Torjesen; William C Miller; Irving Hoffman; Peter Kazembe; Charles Mwansambo Journal: Trop Med Int Health Date: 2009-06-28 Impact factor: 2.622
Authors: Maureen Braun; Mark M Kabue; Eric D McCollum; Saeed Ahmed; Maria Kim; Leela Aertker; Marko Chirwa; Michael Eliya; Innocent Mofolo; Irving Hoffman; Peter N Kazembe; Charles van der Horst; Mark W Kline; Mina C Hosseinipour Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Christina Psaros; Jennifer A Smit; Nzwakie Mosery; Kara Bennett; Jessica N Coleman; David R Bangsberg; Steven A Safren Journal: Ann Behav Med Date: 2020-09-01
Authors: Elizabeth Brown; Benjamin H Chi; Jennifer S Read; Taha E Taha; Usha Sharma; Irving F Hoffman; Cheryl Pikora; Robert Goldenberg; Susan A Fiscus Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Eric D McCollum; Geoffrey A Preidis; Mark M Kabue; Emmanuel B M Singogo; Charles Mwansambo; Peter N Kazembe; Mark W Kline Journal: PLoS One Date: 2010-03-10 Impact factor: 3.240